Farrell Mendelsohn, MD
Cardiovascular Disease · Birmingham, ALNPI 1770548307
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $37,175 of the $50,647 with a category attached, or 73.4%. 38 manufacturers reported payments, led by Medtronic at 56.1% of the total. Reporting peaked in 2021 at $14,906 and has fallen 96.8% since, to $479 in 2025. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 289 payments — averaging $175.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$28K
- Biocardia, Inc.$18K
- Novartis$647
- Amgen$494
- Actelion Pharmaceuticals US, Inc.$445
- Sanofi-aventis U.S. LLC$352
- plus $3K from 32 others
Across 290 payments — averaging $689.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$55K
- Boehringer Ingelheim$53K
- CSL Behring$35K
- Modernatx, Inc.$25K
- Boston Scientific$13K
- Boehringer Ingelheim International GmbH$11K
- plus $9K from 2 others
What the payments were for
- Consulting fees$37,17573%
- Speaking & faculty fees$6,41313%
- Travel & lodging$1,4683%
- Food & beverage$5,45011%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 37 | $28,402 |
| Biocardia, Inc. | 2 | $17,600 |
| Novartis | 49 | $647 |
| Amgen | 22 | $494 |
| Actelion Pharmaceuticals US, Inc. | 23 | $445 |
| Sanofi-aventis U.S. LLC | 21 | $352 |
| Pfizer | 20 | $350 |
| AstraZeneca | 18 | $253 |
| Johnson & Johnson | 17 | $215 |
| Amarin Pharma, Inc. | 13 | $199 |
| E.r. Squibb & Sons, L.L.C. | 12 | $188 |
| Preventice Services, LLC | 2 | $187 |
| Akcea Therapeutics, Inc. | 3 | $154 |
| Astellas Pharma US Inc | 3 | $127 |
| Philips North America LLC | 4 | $108 |
| Abbott | 3 | $93 |
| Silk Road Medical, Inc. | 1 | $92 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $90 |
| Novo Nordisk | 4 | $79 |
| Boehringer Ingelheim | 3 | $65 |
| Lexicon Pharmaceuticals, Inc. | 3 | $62 |
| Bayer | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Biosense Webster, Inc. | 1 | $40 |
| Merck | 2 | $36 |
| Irhythm Technologies, Inc. | 2 | $34 |
| Amryt Pharma Holdings Ltd | 2 | $32 |
| Angiodynamics, Inc. | 1 | $30 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Elutia, Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Sobi, Inc | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Cardiovascular Systems Inc. | 1 | $13 |
| Infobionic, Inc | 1 | $12 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$564
- TEGSEDI$121
How this compares
$50,647 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,358 | $985,140 |
| FarxigaDapagliflozin Propanediol | 853 | $548,974 |
| EntrestoSacubitril/Valsartan | 481 | $376,523 |
| Repatha SureclickEvolocumab | 552 | $352,623 |
| XareltoRivaroxaban | 201 | $157,465 |
| JardianceEmpagliflozin | 228 | $139,899 |
| MultaqDronedarone Hcl | 82 | $84,193 |
| Ranolazine ErRanolazine | 441 | $42,814 |
| LivaloPitavastatin Calcium | 72 | $38,097 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 343 | $35,066 |
| Repatha SyringeEvolocumab | 30 | $21,489 |
| Metoprolol Succinate | 1,136 | $21,019 |
| Midodrine Hcl | 190 | $18,841 |
| DapagliflozinDapagliflozin Propanediol | 29 | $16,635 |
| Bumetanide | 436 | $15,039 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $350 | $985,1401,358 claims |
| AstraZenecaFarxiga, Brilinta | $253 | $560,162872 claims |
| NovartisEntresto | $647 | $376,523481 claims |
| Johnson & JohnsonXarelto | $215 | $157,465201 claims |
| Boehringer IngelheimJardiance | $65 | $139,899228 claims |
| Sanofi-aventis U.S. LLCMultaq | $352 | $84,19382 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Charles MooreBirmingham$47K
- Christopher DegroatBirmingham$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.